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ABSTRACT
We designed and synthesised novel N-substituted 1,3-thiazolidin-4-one derivatives for the evaluation of
their anti-Toxoplasma gondii efficacy. This scaffold was functionalised both at the N1-hydrazine portion
with three structurally different moieties and at the lactam nitrogen with substituted benzyl groups
selected on the basis of our previous structure-activity relationships studies. Using three different assay
methods, the compounds were assessed in vitro to determine both the levels of efficacy against the tachy-
zoites of T. gondii (IC50¼ 5–148lM), as well as any evidence of cytotoxicity towards human host cells
(TD50¼ 68 to 320lM). Results revealed that ferrocene-based thiazolidinones can possess potent anti-
tachyzoite activity (TI ¼2–64).
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1. Introduction
Toxoplasma gondii is the eukaryotic pathogen responsible for toxo-
plasmosis, a major parasitic disease of global importance that
afflicts both humans and animals1,2. Toxoplasma gondii is an obli-
gate intracellular parasite endowed with a complex life cycle dur-
ing which the parasite has the ability to differentiate from the
rapidly replicating form (tachyzoite) to the metabolically less active
form (bradyzoite) that is enclosed in a tissue cyst, and vice versa.
Tachyzoites are responsible for establishing an acute infection in
humans and other animals via ingestion of undercooked meat car-
rying parasite tissue cysts, by consumption of foods or water con-
taminated with parasite oocysts disseminated by infected felids, or
via transplacental passage in pregnant women3–5. Formation of
bradyzoite-bearing tissue cysts in the host signals establishment of
the chronic, often quiescent, form of disease. Immune suppression
on the backdrop of such chronic toxoplasmosis can lead to reacti-
vation of acute toxoplasmosis, potentially resulting in further
serious diseases including encephalitis6, development of schizo-
phrenia7,8, spontaneous abortions in pregnant women, and ocular
diseases9.
Toxoplasmosis is currently treated with compounds that have
been associated with severe side effects ranging from intolerance
to allergic reactions10,11. Additionally, these drugs are unable to
completely get rid of the host of parasite tissue cysts, and thus
cannot cure the chronic infection12 leaving infected individuals,
especially immunocompromised hosts, susceptible to serious
sequelae. Many novel and often highly efficacious Toxoplasma
inhibitors have been recently reported, yet complete eradication
of bradyzoite cysts remains elusive13–17. Our objective is to
develop a compound that is highly efficacious against both the
tachyzoites and the bradyzoites of T. gondii with minimal host cell
cytotoxicity. We report here our continuing efforts towards this
objective beginning with a focus on anti-tachyzoite activity.
Pursuing our research on the thiazole derivatives endowed with
anti-Toxoplasma activity and limited cytotoxicity18, we recently
published a new series of thiazolidinones substituted or not with
a benzyl group at the lactam NH19 exploring which substituents at
the N1-hydrazine portion of the lateral chain presented either a
promising anti-Toxoplasma activity in the micromolar range and a
better ability to inhibit the penetration of parasite into the host
cell. Starting from these results, we synthesised 33 thiazolidinone
derivatives and tested them for in vitro anti-parasitic activity using
T. gondii tachyzoites. The newly synthesised compounds, with
respect to the previous series, kept the thiazolidinone pharmaco-
phore constant varying the chemical space at the nitrogen atoms.
After spectroscopic characterisation to ensure purity, the newly
synthesised compounds were evaluated for parasite growth inhib-
ition and cytotoxicity, inhibition of tachyzoite invasion of host
cells, and inhibition of intracellular tachyzoite replication.
2. Chemistry
As outlined in Scheme 1, for the synthesis of compounds 1–33
three different carbonyl compounds (3-heptanone, 2-acetylthio-
phene, and acetylferrocene) were dissolved/suspended in ethyl
alcohol and reacted directly with thiosemicarbazide and catalytic
amounts of acetic acid. The resulting intermediate thiosemicarba-
zones were reacted with ethyl bromoacetate in methanol and
sodium acetate in order to obtain the corresponding 1,3-thiazoli-
din-4-one derivatives20. Finally, the reaction between the resulting
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products and ortho-, meta-, or para-substituted (with nitro groups
and halogens) benzyl bromides or 1-(chloromethyl)naphthalene or
N-(chloromethyl)phthalimide in anhydrous acetone and potassium
carbonate gave the N-benzyl derivatives (1–33). All the synthes-
ised compounds were washed with petroleum ether and diethyl
ether and purified by column chromatography before characterisa-
tion by spectroscopic methods (IR and 1H/13C NMR) and elemen-
tal analysis. Some representative spectra are reported in the
Supplementary materials.
3. Biological characterisation
Using published methods8,19, all of the prepared N-substituted
thiazolidinones derivatives were evaluated in vitro for (i) host cell
cytotoxicity as well as for the ability to inhibit tachyzoite growth
over a period of 5 days (Table 1), for (ii) the ability to inhibit tachy-
zoite invasion of host cells (Figure 1), and for (iii) the ability to
inhibit intracellular tachyzoite replication (Figure 2).
4. Experimental protocols
The chemicals, solvents for synthesis, and spectral grade solvents
were purchased from Aldrich (Italy) and used without further puri-
fication. Melting points (uncorrected) were determined automatic-
ally on an FP62 apparatus (Mettler-Toledo, Colombus, OH). Neat IR
spectra were registered on a Perkin Elmer FT-IR Spectrometer
Spectrum 1000. 1H (and 13C) NMR spectra were recorded at 400
(and 101) MHz on a Bruker spectrometer using CDCl3 or DMSO-d6
as solvent. Chemical shifts are expressed as d units (parts per mil-
lions) relative to the solvent peak. Coupling constants J are valued
in Hertz (Hz). Elemental analyses for C, H, and N were recorded on
a Perkin-Elmer 240 B microanalyzer and the analytical results were
within ±0.4% of the theoretical values for all compounds.
All reactions were monitored by TLC performed on 0.2mm thick
silica gel plates (60 F254 Merck). In general, the IR spectrum for
derivatives 1–33 showed bands at about 3027 cm1 (Csp2-H
stretching), at about 1690 (C¼O stretching), at about 1620 (C¼N
stretching), and at about 1580 and 1440 (C¼C stretching).
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Scheme 1. General synthesis of the derivatives 1–33.
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Table 1. Five-day growth inhibition assay for N-substituted thiazolidinone derivatives 1–33 and reference drugs.
Compound Structure IC50
a lM IC90
b lM TD50
c lM TId
1
N
N
S
N O
O2N
20 111 236 12
2
N
N
S
N O
S
O2N
37 155 280 8
3
N
N
S
N O
Fe
O2N
15 78 320 21
4
N
N
S
N O
O2N
44 138 68 2
5
N
N
S
N O
S
O2N
52 171 320 6
6
N
N
S
N O
Fe
O2N
24 152 320 13
7
N
N
S
N O
NO2
32 128 98 3
8
N
N
S
N O
NO2
S
148 378 320 2
(continued)
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Table 1. Continued
Compound Structure IC50
a lM IC90
b lM TD50
c lM TId
9
N
N
S
N O
Fe
NO2
73 292 217 3
10
N
N
S
N O
F
24 104 90 4
11
N
N
S
N O
S
F
25 103 82 3
12
N
N
S
N O
Fe
F
17 64 320 19
13
N
N
S
N O
F
18 99 246 14
14
N
N
S
N O
S
F
45 147 178 4
15
N
N
S
N O
Fe
F
8 57 320 40
16
N
N
S
N O
F
29 107 192 7
(continued)
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Table 1. Continued
Compound Structure IC50
a lM IC90
b lM TD50
c lM TId
17
N
N
S
N O
S
F
72 312 320 4
18
N
N
S
N O
Fe
F
6 16 320 53
19
N
N
S
N O
Cl
39 183 95 2
20
N
N
S
N O
S
Cl
34 112 84 2
21
N
N
S
N O
Fe
Cl
9 24 320 36
22
N
N
S
N O
Cl
19 106 165 9
23
N
N
S
N O
S
Cl
51 256 147 3
24
N
N
S
N O
Fe
Cl
8 17 320 40
(continued)
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Table 1. Continued
Compound Structure IC50
a lM IC90
b lM TD50
c lM TId
25
N
N
S
N O
Cl
51 131 244 5
26
N
N
S
N O
S
Cl
81 211 320 4
27
N
N
S
N O
Fe
Cl
10 55 320 32
28
N
N
S
N O
37 138 271 7
29
N
N
S
N O
S
35 122 320 9
30
N
N
S
N O
Fe
5 17 320 64
31
N
N
S
N O
N O
O
88 402 320 4
(continued)
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Some representative spectra were reported in the Supplementary
materials.
4.1. General procedure for the synthesis of compounds 1–33
The initial carbonyl compound (50mmol) was dissolved/suspended
in ethanol (50ml) and magnetically stirred with thiosemicarbazide
(50mmol) and catalytic amounts of acetic acid for 8–24 h at room
temperature. The obtained thiosemicarbazone was filtered, washed
with appropriate solvent (n-hexane, petroleum ether, or diethyl
ether) and dried under vacuum overnight. The intermediate thio-
semicarbazone (50mmol) reacted with ethyl bromoacetate
(50mmol), in methanol (50ml) and sodium acetate (50mmol) at
room temperature under magnetic stirring for 24 h. The resulting
4-thiazolidinone was poured on ice, filtered or extracted with
chloroform (3 30ml) and purified by column chromatography
(SiO2, ethyl acetate/n-hexane). Then, the resulting thiazolidinone
(50mmol) was dissolved/suspended in 50ml of anhydrous acetone
in the presence of anhydrous potassium carbonate (50mmol), and
reacted with equimolar amounts of 2-,3-,4-nitrobenzyl bromide,
2-,3-,4-chlorobenzyl bromide, 2-,3-,4-fluorobenzyl bromide,
1-(chloromethyl)naphthalene or N-(chloromethyl)phthalimide for
24–48 h. The products were poured on ice, filtered or extracted
with chloroform (3 50ml) and purified by column chromatog-
raphy (SiO2, ethyl acetate/n-hexane) in order to obtain the title
compounds in high yields as previously reported20.
4.1.1. 2-((Heptan-3-ylidene)hydrazono)-3-(2-nitrobenzyl)
thiazolidin-4-one (1)
White powder, mp 67–69 C, 95% yield; 1H NMR (400MHz, DMSO-
d6): d 0.66–0.69 (m, 3H, CH3), 0.85–0.88 (m, 3H, CH3), 1.26–1.29
Table 1. Continued
Compound Structure IC50
a lM IC90
b lM TD50
c lM TId
32
N
N
S
N O
N
S
O
O
78 219 117 2
33
N
N
S
N O
N
Fe
O
O
82 286 138 2
Sulfadiazine 43 219 281 7
Atovaquone 0.2 2 24 133
aIC50¼Median inhibitory concentration, a measure of tachyzoite inhibition.
bIC90¼ Concentration at which 90% of the tachyzoite growth is inhibited.
cTD50¼Median toxicity dose, a measure of cytotoxicity against host cells.
dTI¼ Therapeutic index, a measure of efficacy, calculated by TD50/IC50. When TD50320 TI¼ 320/IC50.
Figure 1. Invasion assay of ferrocene-based thiazolidinone derivatives (10lM). VHL: vehicle (DMSO). Significant inhibition of tachyzoite invasion (p .05, two-tailed
Students’ t test). Significant inhibition of tachyzoite attachment (p .05, two-tailed Students’ t test). Data are compiled from results of three independent
experiments.
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(m, 2H, CH2), 1.41–1.46 (m, 2H, CH2), 2.07–2.09 (m, 2H, CH2),
2.18–2.22 (m, 2H, CH2), 4.04 (s, 2H, CH2, thiazolidinone), 5.13 (s,
2H, ArCH2), 7.36–7.40 (m, 1 H, Ar), 7.56–7.58 (m, 1H, Ar), 7.68–7.74
(m, 1H, Ar), 8.06–8.08 (m, 1H, Ar). 13C NMR (101MHz, DMSO-d6) d
10.9 (CH3), 14.3 (CH3), 22.3 (CH2), 28.1 (CH2), 29.7 (CH2), 32.6 (CH2),
35.6 (CH2, thiazolidinone), 42.9 (CH2), 125.2 (Ar), 128.6 (Ar), 129.1
(Ar), 131.4 (Ar), 134.4 (Ar), 148.7 (Ar), 158.3 (C¼N, thiazolidinone),
159.6 (C¼N), 172.7 (C¼O). Anal. Calcd for C17H22N4O3S: C, 56.33;
H, 6.12; N, 15.46. Found: C, 56.67; H, 6.31; N, 15.20.
4.1.2. 3-(2-Nitrobenzyl)-2-((1-(thiophen-2-yl)ethylidene)hydrazono)-
thiazolidin-4-one (2)
Pink powder, mp 150–151 C, 93% yield; 1H NMR (400MHz,
CDCl3): d 2.26 (s, 3 H, CH3), 3.90 (s, 2 H, CH2, thiazolidinone), 5.44
(s, 2 H, ArCH2), 7.05–7.06 (m, 1 H, thiophene), 7.32–7.48 (m, 4 H,
thiopheneþAr), 7.59–7.61 (m, 1H, Ar), 8.07–8.09 (m, 1H, Ar). Anal.
Calcd for C16H14N4O3S2: C, 51.32; H, 3.77; N, 14.96. Found C, 51.65;
H, 3.50; N, 15.11.
4.1.3. 3-(2-Nitrobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)hydrazono)-
thiazolidin-4-one (3)
Red powder, mp 195–198 C, 90% yield; 1H NMR (400MHz, DMSO-
d6): d 2.02 (s, 3H, CH3), 4.05 (s, 2H, CH2, thiazolidinone), 4.15–4.17
(m, 5H, ferrocene), 4.41 (s, 2H, ferrocene), 4.65 (s, 2H, ferrocene),
5.21 (s, 2H, ArCH2), 7.46–7.47 (t, 1H, Ar), 7.58–7.59 (m, 1H, Ar),
7.73–7.75 (m, 1H, Ar), 8.08–8.10 (d, J¼ 7.2 Hz, 1 H, Ar). 13C NMR
(101MHz, DMSO-d6) d 15.8 (CH3), 32.7 (CH2, thiazolidinone), 42.9
(CH2), 67.8 (CH2, ferrocene), 69.7 (CH2, ferrocene), 70.6 (CH, ferro-
cene), 82.8 (C, ferrocene), 125.2 (Ar), 129.0 (Ar), 129.2 (Ar) 131.3
(Ar), 134.5 (Ar), 148.8 (Ar), 159.2 (C¼N, thiazolidinone), 164.6
(C¼N), 172.8 (C¼O). Anal. Calcd for C22H20FeN4O3S: C, 55.47; H,
4.23; N, 11.76. Found: C, 55.23; H, 4.45; N, 11.98.
4.1.4. 2-((Heptan-3-ylidene)hydrazono)-3–(3-nitrobenzyl)
thiazolidin-4-one (4)
Yellow oil, 65% yield; 1H NMR (400MHz, DMSO-d6): d 0.64–0.69 (m,
6H, 2  CH3), 0.82–0.84 (m, 1H, CH2), 1.09–1.11 (m, 2H, CH2),
1.26–1.28 (m, 1H, CH2), 2.02–2.12 (m, 4H, 2  CH2), 3.79 (s, 2H,
CH2, thiazolidinone), 4.77 (s, 2H, ArCH2), 7.42–7.47 (m, 1H, Ar),
7.54–7.59 (m, 1H, Ar), 7.94–7.95 (m, 2H, Ar). 13C NMR (101MHz,
DMSO-d6) d 11.0 (CH3), 14.0 (CH3), 22.7 (CH2), 28.5 (CH2), 29.6
(CH2), 30.8 (CH2), 32.5 (CH2, thiazolidinone), 45.6 (CH2), 122.9 (Ar),
123.0 (Ar), 130.4 (Ar), 134.7 (Ar), 139.0 (Ar), 148.2 (Ar), 158.9 (C¼N,
thiazolidinone), 160.4 (C¼N), 172.7 (C¼O). Anal. Calcd for
C17H22N4O3S: C, 56.33; H, 6.12; N, 15.46. Found: C, 56.59; H, 5.94;
N, 15.25.
4.1.5. 3-(3-Nitrobenzyl)-2-((1-(thiophen-2-yl)ethylidene)hydrazono)-
thiazolidin-4-one (5)
Yellow powder, mp 165–170 C, 82% yield; 1H NMR (400MHz,
DMSO-d6): d 2.36 (s, 3H, CH3), 4.05 (s, 2H, CH2, thiazolidinone), 5.05
(s, 2H, ArCH2), 7.11–7.13 (m, 1H, thiophene), 7.54–7.55 (m, 1H, thio-
phene), 7.61–7.62 (m, 1H, thiophene), 7.65–7.69 (m, 1H, Ar),
7.83–7.85 (m, 1H, Ar), 8.17–8.19 (m, 1H, Ar), 8.30 (s, 1H, Ar). Anal.
Calcd for C16H14N4O3S2: C, 51.32; H, 3.77; N, 14.96. Found: C, 51.19;
H, 3.95; N, 15.16.
4.1.6. 3-(3-Nitrobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)hydrazono)-
thiazolidin-4-one (6)
Red powder, mp 171–173 C, 83% yield; 1H NMR (400MHz, DMSO-
d6): d 2.22 (s, 3H, CH3), 4.01 (s, 2H, CH2, thiazolidinone), 4.17 (s, 5H,
ferrocene), 4.43 (s, 2H, ferrocene), 4.69 (s, 2H, ferrocene), 5.03 (s,
2H, ArCH2), 7.66–7.70 (t, 1H, Ar), 7.84–7.86 (d, J¼ 7.2 Hz, 1H, Ar),
8.18–8.19 (d, J¼ 7.2 Hz, 1H, Ar), 8.32 (s, 1H, Ar). 13C NMR (101MHz,
DMSO-d6) d 16.2 (CH3), 32.5 (CH2, thiazolidinone), 45.6 (CH2), 67.8
(CH2, ferrocene), 69.7 (CH2, ferrocene), 70.6 (CH, ferrocene), 82.9 (C,
ferrocene), 123.1 (Ar), 123.7 (Ar), 130.5 (Ar), 135.5 (Ar), 138.8 (Ar),
148.2 (Ar), 159.8 (C¼N, thiazolidinone), 164.6 (C¼N), 172.8
(C¼O). Anal. Calcd for C22H20FeN4O3S: C, 55.47; H, 4.23; N, 11.76.
Found: C, 55.68; H, 4.11; N, 11.57.
4.1.7. 2-((Heptan-3-ylidene)hydrazono)-3-(4-nitrobenzyl)
thiazolidin-4-one (7)
Yellow oil, 63% yield; 1H NMR (400MHz, CDCl3): d 0.86–0.89 (t, 3H,
CH3), 0.93–1.01 (m, 2H, CH2), 1.13–1.18 (m, 1H, CH2), 1.22–1.31 (m,
2H, CH2), 1.35–1.42 (m, 1H, CH2), 1.54–1.62 (m, 1H, CH2), 2.31–2.43
Figure 2. Replication assay of ferrocene-based thiazolidinone derivatives (10lM). VHL: vehicle (DMSO); Tz: tachyzoites. Data are compiled from results of three inde-
pendent experiments.
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(m, 1H, CH2, 3H, CH3), 3.81 (s, 2H, CH2, thiazolidinone), 5.07 (s, 2H,
ArCH2), 7.56–7.61 (m, 2H, Ar), 8.18–8.20 (d, J¼ 8.8 Hz, 2H, Ar). 13C
NMR (101MHz, DMSO-d6) d 11.0 (CH3), 14.0 (CH3), 22.8 (CH2), 28.6
(CH2), 29.6 (CH2), 30.9 (CH2), 32.5 (CH2, thiazolidinone), 45.7 (CH2),
124.0 (Ar), 128.7 (Ar), 128.8 (Ar), 129.2 (Ar), 144.6 (Ar), 147.2 (Ar),
158.7 (C¼N, thiazolidinone), 160.1 (C¼N), 172.6 (C¼O). Anal.
Calcd for C17H22N4O3S: C, 56.33; H, 6.12; N, 15.46. Found: C, 56.19;
H, 6.27; N, 15.68.
4.1.8. 3-(4-Nitrobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)hydrazono)-
thiazolidin-4-one (9)
Red powder, mp 214–217 C, 84% yield; 1H NMR (400MHz, DMSO-
d6): d 2.15 (s, 3H, CH3), 4.03 (s, 2H, CH2, thiazolidinone), 4.17 (s, 5H,
ferrocene), 4.42 (s, 2H, ferrocene), 4.67 (s, 2H, ferrocene), 5.04 (s,
2H, ArCH2), 7.64–7.66 (d, J¼ 8.8 Hz, 2 H, Ar), 8.23–8.25 (d,
J¼ 8.8 Hz, 2H, Ar). 13C NMR (101MHz, DMSO-d6) d 16.2 (CH3), 32.6
(CH2, thiazolidinone), 45.8 (CH2), 67.8 (CH2, ferrocene), 69.7 (CH2,
ferrocene), 70.6 (CH, ferrocene), 82.9 (C, ferrocene), 124.0 (Ar),
129.4 (Ar), 144.4 (Ar), 147.4 (Ar), 159.5 (C¼N, thiazolidinone), 164.6
(C¼N), 172.7 (C¼O). Anal. Calcd for C22H20FeN4O3S: C, 55.47; H,
4.23; N, 11.76. Found: C, 55.68; H, 4.11; N, 11.57.
4.1.9. 3-(2-Fluorobenzyl)-2-((heptan-3-ylidene)hydrazono)
thiazolidin-4-one (10)
Yellow oil, 64% yield; 1H NMR (400MHz, DMSO-d6): d 0.75–0.80 (m,
3H, CH3), 0.85–0.90 (m, 3H, CH3), 1.27–1.32 (m, 2H, CH2), 1.42–1.48
(m, 2H, CH2), 2.21–2.26 (m, 4H, 2  CH2), 4.00 (s, 2H, CH2, thiazoli-
dinone), 4.91 (s, 2H, ArCH2), 7.12–7.35 (m, 4H, Ar).
13C NMR
(101MHz, DMSO-d6) d 11.0 (CH3), 14.1 (CH3), 22.7 (CH2), 28.5 (CH2),
29.6 (CH2), 30.8 (CH2), 32.4 (CH2, thiazolidinone), 35.6 (CH2), 115.7
(Ar), 123.4 (Ar), 124.8 (Ar), 129.4 (Ar), 129.8 (Ar), 159.2 (C¼N, thia-
zolidinone), 160.1 (C¼N), 161.7 (Ar, C-F), 172.5 (C¼O). Anal. Calcd
for C17H22FN3OS: C, 60.87; H, 6.61; N, 12.53. Found: C, 60.54; H,
6.39; N, 12.68.
4.1.10. 3-(2-Fluorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (11)
Orange powder, mp 80–85 C, 91% yield; 1H NMR (400MHz,
DMSO-d6): d 2.28 (s, 3H, CH3), 4.06 (s, 2H, CH2, thiazolidinone), 4.98
(s, 2H, ArCH2), 7.10–7.21 (m, 3H, thiophene), 7.33–7.36 (m, 2H, Ar),
7.51–7.52 (m, 1H, Ar), 7.61–7.62 (m, 1H, Ar). Anal. Calcd for
C16H14FN3OS2: C, 55.31; H, 4.06; N, 12.09. Found: C, 55.60; H, 3.83;
N, 12.21.
4.1.11. 3-(2-Fluorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (12)
Red oil, 65% yield; 1H NMR (400MHz, DMSO-d6): d 2.14 (s, 3H,
CH3), 4.02 (s, 2H, CH2, thiazolidinone), 4.16 (s, 5H, ferrocene), 4.42
(s, 2H, ferrocene), 4.67 (s, 2H, ferrocene), 4.96 (s, 2H, ArCH2),
7.19–7.24 (m, 2H, Ar), 7.33–7.38 (m, 2H, Ar). 13C NMR (101MHz,
DMSO-d6) d 16.0 (CH3), 32.4 (CH2, thiazolidinone), 67.8 (CH2, ferro-
cene), 69.7 (CH2, ferrocene), 70.5 (CH, ferrocene), 82.9 (C, ferro-
cene), 115.7 (Ar), 123.4 (Ar), 124.8 (Ar), 129.9 (Ar), 130.1 (Ar), 159.4
(C¼N, thiazolidinone), 161.8 (Ar, C–F), 164.4 (C¼N), 172.5 (C¼O).
Anal. Calcd for C22H20FFeN3OS: C, 58.81; H, 4.49; N, 9.35. Found: C,
58.69; H, 4.22; N, 9.07.
4.1.12. 3-(3-Fluorobenzyl)-2-((heptan-3-ylidene)hydrazono)thiazoli-
din-4-one (13)
Yellow powder, mp 30–31 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 0.55–0.59 (m, 1H, CH2), 0.62–0.70 (m, 3 H, CH3),
0.81–0.85 (m, 1 H, CH2), 0.92–1.12 (m, 4 H, 2  CH2), 1.27–1.31 (m,
1 H, CH2), 2.03–2.12 (m, 4 H, CH2þCH3), 3.79 (s, 2 H, CH2, thiazolidi-
none), 4.66 (s, 2 H, ArCH2), 6.88–6.96 (m, 3H, Ar), 7.15–7.23 (m, 1H,
Ar). 13C NMR (101MHz, DMSO-d6) d 11.0 (CH3), 14.3 (CH3),
22.3 (CH2), 28.2 (CH2), 29.6 (CH2), 30.9 (CH2), 32.4 (CH2, thiazolidi-
none), 45.7 (CH2), 115.2 (Ar), 123.9 (Ar), 124.2 (Ar), 130.8 (Ar),
139.5 (Ar), 160.0 (C¼N, thiazolidinone), 160.4 (C¼N), 162.5 (d,
JC–F¼ 244.4Hz, Ar, C–F), 172.6 (C¼O). Anal. Calcd for
C17H22FN3OS: C, 60.87; H, 6.61; N, 12.53. Found: C, 60.61; H, 6.82;
N, 12.36.
4.1.13. 3-(3-Fluorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (14)
Yellow powder, mp 84–85 C, 89% yield; 1H NMR (400MHz, DMSO-
d6): d 2.33 (s, 3 H, CH3), 4.05 (s, 2 H, CH2, thiazolidinone), 4.93 (s, 2 H,
ArCH2), 7.12–7.22 (m, 4H, thiopheneþAr), 7.38–7.41 (m, 1 H, Ar),
7.53 (bs, 1 H, Ar), 7.61–7.63 (m, 1 H, Ar). Anal. Calcd for
C16H14FN3OS2: C, 55.31; H, 4.06; N, 12.09. Found: C, 55.56; H, 3.79; N,
11.84.
4.1.14. 3-(3-Fluorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (15)
Brown oil, 69% yield; 1H NMR (400MHz, DMSO-d6): d 2.19 (s, 3H,
CH3), 4.01 (s, 2H, CH2, thiazolidinone), 4.17 (s, 5H, ferrocene), 4.42
(s, 2H, ferrocene), 4.68 (s, 2H, ferrocene), 4.92 (s, 2 H, ArCH2),
7.12–7.23 (m, 3 H, Ar), 7.40–7.42 (m, 1H, Ar). 13C NMR (101MHz,
DMSO-d6) d 16.2 (CH3), 32.5 (CH2, thiazolidinone), 45.8 (CH2), 67.8
(CH2, ferrocene), 69.7 (CH2, ferrocene), 70.6 (CH, ferrocene), 82.9 (C,
ferrocene), 114.8 (Ar), 115.2 (Ar), 124.4 (Ar), 130.9 (Ar), 139.4 (Ar),
159.7 (C¼N, thiazolidinone), 162.5 (d, JC–F¼ 244.3Hz, Ar, C–F),
164.4 (C¼N), 172.7 (C¼O). Anal. Calcd for C22H20FFeN3OS: C,
58.81; H, 4.49; N, 9.35. Found: C, 58.99; H, 4.65; N, 9.51.
4.1.15. 3–(4-Fluorobenzyl)-2-((heptan-3-ylidene)hydrazono)
thiazolidin-4-one (16)
Yellow oil, 67% yield; 1H NMR (400MHz, DMSO-d6): d 0.78–0.81 (m,
1H, CH2), 0.86–0.90 (t, 3H, CH3), 1.02–1.05 (m, 2H, CH2), 1.12–1.16
(m, 1H, CH2), 1.25–1.34 (m, 2H, CH2), 1.47–1.51 (m, 1H, CH2),
2.24–2.34 (m, 4H, CH2þCH3), 3.97 (s, 2H, CH2, thiazolidinone), 4.83
(s, 2 H, ArCH2), 7.12–7.18 (m, 2H, Ar), 7.34–7.38 (m, 2H, Ar).
13C
NMR (101MHz, DMSO-d6) d 11.0 (CH3), 14.1 (CH3), 22.8 (CH2), 28.6
(CH2), 29.6 (CH2), 31.0 (CH2), 32.4 (CH2, thiazolidinone), 45.5 (CH2),
115.4 (Ar), 115.7 (Ar),130.1 (Ar), 130.2 (Ar) 132.9 (Ar), 160.4 (C¼N,
thiazolidinone), 160.8 (Ar, C–F), 163.2 (C¼N), 172.6 (C¼O). Anal.
Calcd for C17H22FN3OS: C, 60.87; H, 6.61; N, 12.53. Found: C, 61.02;
H, 6.77; N, 12.70.
4.1.16. 3-(4-Fluorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (17)
Pink powder, mp 118–123 C, 80% yield; 1H NMR (400MHz, CDCl3):
d 2.47 (s, 3H, CH3), 3.81 (s, 2 H, CH2, thiazolidinone), 5.00 (s, 2H,
ArCH2), 6.93–7.08 (m, 3H, thiophene), 7.22–7.52 (m, 4H, Ar). Anal.
Calcd for C16H14FN3OS2: C, 55.31; H, 4.06; N, 12.09. Found: C,
55.06; H, 3.91; N, 11.84.
4.1.17. 3-(4-Fluorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (18)
Red powder, mp 122–127 C, 82% yield; 1H NMR (400MHz, DMSO-
d6): d 2.22 (s, 3H, CH3), 3.98 (s, 2H, CH2, thiazolidinone), 4.17 (s, 5H,
ferrocene), 4.42 (s, 2H, ferrocene), 4.69 (s, 2H, ferrocene), 4.89
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(s, 2H, ArCH2), 7.17–7.21 (m, 2H, Ar), 7.43–7.462 (m, 2H, Ar).
13C NMR (101MHz, DMSO-d6) d 16.2 (CH3), 32.5 (CH2, thiazolidi-
none), 45.6 (CH2), 67.8 (CH2, ferrocene), 69.7 (CH2, ferrocene), 70.6
(CH, ferrocene), 83.0 (C, ferrocene), 115.5 (Ar), 115.7 (Ar), 130.7
(Ar), 130.8 (Ar), 132.9 (Ar), 159.8 (C¼N, thiazolidinone), 162.1 (d,
JC–F¼ 244.4 Hz, Ar, C–F), 164.4 (C¼N), 172.6 (C¼O). Anal. Calcd
for C22H20FFeN3OS: C, 58.81; H, 4.49; N, 9.35. Found: C, 59.04; H,
4.71; N, 9.47.
4.1.18. 3-(2-Chlorobenzyl)-2-((heptan-3-ylidene)hydrazono)
thiazolidin-4-one (19)
Orange oil, 60% yield; 1H NMR (400MHz, DMSO-d6): d 0.66–0.76
(m, 3H, CH3), 0.85–0.90 (m, 1H, CH2), 1.00–1.05 (m, 2H, CH2),
1.12–1.20 (m, 1H, CH2), 1.25–1.32 (m, 2H, CH2), 1.43–1.48 (m, 1H,
CH2), 2.16–2.26 (m, 4H, CH2þCH3), 4.05 (s, 2H, CH2, thiazolidi-
none), 4.93 (s, 2H, ArCH2), 7.13–7.20 (m, 1H, Ar), 7.27–7.31 (m, 2H,
Ar), 7.45–7.48 (m, 1H, Ar). 13C NMR (101MHz, CDCl3) d 10.6 (CH3),
13.8 (CH3), 22.8 (CH2), 28.7 (CH2), 30.0 (CH2), 31.2 (CH2), 32.4 (CH2,
thiazolidinone), 44.2 (CH2), 126.8 (Ar), 127.6 (Ar), 128.1 (Ar), 128.5
(Ar), 129.5 (Ar), 132.9 (Ar), 156.9 (C¼N, thiazolidinone), 158.7
(C¼N), 171.9 (C¼O). Anal. Calcd for C17H22ClN3OS: C, 58.02; H,
6.30; N, 11.94. Found: C, 58.14; H, 6.11; N, 11.76.
4.1.19. 3-(2-Chlorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (20)
Pink powder, mp 100–102 C, 87% yield; 1H NMR (400MHz, CDCl3):
d 2.31 (s, 3H, CH3), 3.90 (s, 2H, CH2, thiazolidinone), 5.18 (s, 2H,
ArCH2), 7.05–7.06 (m, 1H, thiophene), 7.22 (bs, 3H: 2H thiophene
þ1H Ar), 7.36–7.41 (m, 3H, Ar). Anal. Calcd for C16H14ClN3OS2: C,
52.81; H, 3.88; N, 11.55. Found: C, 52.66; H, 3.63; N, 11.24.
4.1.20. 3-(2-Chlorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (21)
Red powder, mp 143–148 C, 83% yield; 1H NMR (400MHz, DMSO-
d6): d 2.08 (s, 3H, CH3), 4.06 (s, 2H, CH2, thiazolidinone), 4.13 (s, 5H,
ferrocene), 4.41 (s, 2H, ferrocene), 4.66 (s, 2H, ferrocene), 5.00 (s,
2H, ArCH2), 7.24 (bs, 1H, Ar), 7.33 (bs, 2H, Ar), 7.50 (bs, 1H, Ar).
13C
NMR (101MHz, DMSO-d6) d 16.0 (CH3), 32.6 (CH2, thiazolidinone),
44.0 (CH2), 67.8 (CH2, ferrocene), 69.7 (CH2, ferrocene), 70.5 (CH,
ferrocene), 82.9 (C, ferrocene), 127.7 (Ar), 128.5 (Ar), 129.5 (Ar),
129.8 (Ar), 132.3 (Ar), 133.5 (Ar), 159.4 (C¼N, thiazolidinone), 164.4
(C¼N), 172.6 (C¼O). Anal. Calcd for C22H20ClFeN3OS: C, 56.73; H,
4.33; N, 9.02. Found: C, 56.55; H, 4.15; N, 9.21.
4.1.21. 3-(3-Chlorobenzyl)-2-((heptan-3-ylidene)hydrazono)
thiazolidin-4-one (22)
Yellow oil, 68% yield; 1H NMR (400MHz, DMSO-d6): d 0.77–0.81 (m,
2H, CH2), 0.86–0.90 (m, 3H, CH3), 1.02–1.06 (m, 2H, CH2), 1.21–1.26
(m, 2H, CH2), 1.48–1.52 (m, 1H, CH2), 2.24–2.35 (m, 4H, CH2þCH3),
3.98 (s, 2H, CH2, thiazolidinone), 4.85 (s, 2H, ArCH2), 7.28–7.40 (m,
4H, Ar). 13C NMR (101MHz, DMSO-d6) d 11.0 (CH3), 14.1 (CH3), 22.8
(CH2), 28.6 (CH2), 29.6 (CH2), 30.9 (CH2), 32.4 (CH2, thiazolidinone),
45.7 (CH2), 126.7 (Ar), 127.9 (Ar), 130.7 (Ar), 133.5 (Ar), 139.1 (Ar),
139.2 (Ar), 158.9 (C¼N, thiazolidinone), 160.4 (C¼N), 172.7
(C¼O). Anal. Calcd for C17H22ClN3OS: C, 58.02; H, 6.30; N, 11.94.
Found: C, 58.28; H, 6.08; N, 11.81.
4.1.22. 3-(3-Chlorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (23)
Pink powder, mp 129–131 C, 89% yield; 1H NMR (400MHz, CDCl3):
d 2.26 (s, 3H, CH3), 3.62 (s, 2H, CH2, thiazolidinone), 4.78 (s, 2H,
ArCH2), 6.85–6.88 (m, 1H, thiophene), 7.05–7.08 (m, 3H,
thiopheneþAr), 7.17–7.20 (m, 2H, Ar), 7.31 (s, 1H, Ar). Anal. Calcd
for C16H14ClN3OS2: C, 52.81; H, 3.88; N, 11.55. Found: C, 52.99; H,
3.69; N, 11.73.
4.1.23. 3-(3-Chlorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (24)
Red powder, mp 143–144 C, 87% yield; 1H NMR (400MHz, DMSO-
d6): d 2.21 (s, 3 H, CH3), 4.01 (s, 2 H, CH2, thiazolidinone), 4.17 (s,
5 H, ferrocene), 4.43 (s, 2 H, ferrocene), 4.69 (s, 2 H, ferrocene), 4.90
(s, 2 H, ArCH2), 7.36–7.40 (m, 3H, Ar), 7.47 (s, 1 H, Ar).
13C NMR
(101MHz, DMSO-d6) d 16.2 (CH3), 32.5 (CH2, thiazolidinone), 45.7
(CH2), 67.8 (CH2, ferrocene), 69.7 (CH2, ferrocene), 70.6 (CH, ferro-
cene), 82.9 (C, ferrocene), 127.2 (Ar), 128.0 (Ar), 128.5 (Ar), 130.8
(Ar), 133.4 (Ar), 139.1 (Ar), 159.7 (C¼N, thiazolidinone), 164.5
(C¼N), 172.7 (C¼O). Anal. Calcd for C22H20ClFeN3OS: C, 56.73; H,
4.33; N, 9.02. Found: C, 56.90H, 4.04; N, 9.18.
4.1.24. 3-(4-Chlorobenzyl)-2-((heptan-3-ylidene)hydrazono)
thiazolidin-4-one (25)
White oil, 60% yield; 1H NMR (400MHz, DMSO-d6): d 0.54–0.57 (m,
2H, CH2), 0.62–0.70 (m, 3H, CH3), 0.81–0.84 (q, 2H, CH2), 0.89–0.93
(m, 1H, CH2), 1.08–1.13 (m, 1H, CH2), 1.27–1.30 (m, 1H, CH2),
2.03–2.11 (m, 4H, CH2þCH3), 3.78 (s, 2H, CH2, thiazolidinone), 4.63
(s, 2H, ArCH2), 7.11–7.19 (m, 4H, Ar).
13C NMR (101MHz, DMSO-d6)
d 11.0 (CH3), 14.1 (CH3), 22.8 (CH2), 28.6 (CH2), 29.6 (CH2), 31.0
(CH2), 32.4 (CH2, thiazolidinone), 45.6 (CH2), 128.8 (Ar), 129.8 (Ar),
132.5 (Ar), 135.7 (Ar), 158.8 (C¼N, thiazolidinone), 160.2 (C¼N),
172.6 (C¼O). Anal. Calcd for C17H22ClN3OS: C, 58.02; H, 6.30; N,
11.94. Found: C, 57.81; H, 6.64; N, 12.16.
4.1.25. 3-(4-Chlorobenzyl)-2-((1-(thiophen-2-yl)ethylidene)
hydrazono)thiazolidin-4-one (26)
White powder, mp 146–151 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 2.34 (s, 3 H, CH3), 4.03 (s, 2 H, CH2, thiazolidinone),
4.90 (s, 2 H, ArCH2), 7.12 (bs, 1 H, thiophene), 7.41 (bs, 4 H, Ar), 7.54
(bs, 1 H, thiophene), 7.61–7.62 (m, 1 H, thiophene). Anal. Calcd for
C16H14ClN3OS2: C, 52.81; H, 3.88; N, 11.55. Found: C, 53.05; H, 4.02;
N, 11.32.
4.1.26. 3-(4-Chlorobenzyl)-2-((1-(ferrocen-2-yl)ethylidene)hydrazo-
no)thiazolidin-4-one (27)
Red powder, mp 167–169 C, 87% yield; 1H NMR (400MHz, DMSO-
d6): d 2.21 (s, 3H, CH3), 3.99 (s, 2H, CH2, thiazolidinone), 4.17 (s, 5H,
ferrocene), 4.42 (s, 2H, ferrocene), 4.68 (s, 2H, ferrocene), 4.89 (s,
2H, ArCH2), 7.42 (bs, 4H, Ar).
13C NMR (101MHz, DMSO-d6) d 16.2
(CH3), 32.5 (CH2, thiazolidinone), 45.6 (CH2), 67.8 (CH2, ferrocene),
69.7 (CH2, ferrocene), 70.6 (CH, ferrocene), 82.9 (C, ferrocene),
128.8 (Ar), 130.4 (Ar), 132.7 (Ar), 135.7 (Ar), 159.8 (C¼N, thiazolidi-
none), 164.4 (C¼N), 172.6 (C¼O). Anal. Calcd for C22H20ClFeN3OS:
C, 56.73; H, 4.33; N, 9.02. Found: C, 56.95 H, 4.57; N, 8.83.
4.1.27. 2-((Heptan-3-ylidene)hydrazono)-3-(naphthalen-1-ylme-
thyl)thiazolidin-4-one (28)
Orange oil, 65% yield; 1H NMR (400MHz, CDCl3): d 0.83–0.87
(t, 3 H, CH3), 0.92–0.96 (t, 3 H, CH3), 1.23–1.37 (m, 5H, CH2),
2.26–2.34 (m, 3 H, CH2), 3.84 (s, 2 H, CH2, thiazolidinone), 5.46 (s,
2 H, ArCH2), 7.40–7.58 (m, 4H, Ar), 7.80–7.92 (m, 2H, Ar), 8.21–8.27
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(m, 1 H, Ar). Anal. Calcd for C21H25N3OS: C, 68.63; H, 6.86; N, 11.43.
Found: C, 68.81; H, 6.99; N, 11.60.
4.1.28. 3-(Naphthalen-1-ylmethyl)-2-((1-(ferrocen-2-yl)ethylidene)-
hydrazono)thiazolidin-4-one (30)
Red oil, 63% yield; 1H NMR (400MHz, DMSO-d6): d 2.08 (s, 3 H,
CH3), 4.07 (s, 2 H, CH2, thiazolidinone), 4.15 (s, 5 H, ferrocene), 4.41
(s, 2 H, ferrocene), 4.66 (s, 2 H, ferrocene), 5.38 (s, 2 H, ArCH2),
7.43–7.62 (m, 4 H, Ar), 7.88–7.90 (m, 1H, Ar), 7.98–7.99 (m, 1H, Ar),
8.31–8.33 (m, 1H, Ar). Anal. Calcd for C26H23FeN3OS: C, 64.87; H,
4.82; N, 8.73. Found: C, 64.59; H, 4.64; N, 8.91.
4.1.29. 2-((2-((Heptan-3-ylidene)hydrazono)-4-oxothiazolidin-3-
yl)methyl)isoindoline-1,3-dione (31)
Yellow oil, 86% yield; 1H NMR (400MHz, CDCl3): d 0.82–0.93 (m,
2H, CH2, 3 H, CH3), 1.08–1.12 (m, 1H, CH2), 1.30–1.37 (m, 3H, CH3),
1.51–1.55 (m, 1H, CH2), 2.24–2.32 (m, 2H, CH2), 2.36–2.44 (m, 2H,
CH2), 3.82 (s, 2H, CH2, thiazolidinone), 5.71 (s, 2H, ArCH2), 7.73–75
(m, 2H, Ar), 7.85–7.86 (m, 2H, Ar). Anal. Calcd for C19H22N4O3S: C,
59.05; H, 5.74; N, 14.50. Found: C, 59.31; H, 5.99; N, 14.21.
4.1.30. 2-((4-Oxo-2-((1-(ferrocen-2-yl)ethylidene)hydrazono)thiazoli-
din-3-yl)methyl)isoindoline-1,3-dione (33)
Red powder, mp 235–237 C, 91% yield; 1H NMR (400MHz, DMSO-
d6): d 2.08 (s, 3H, CH3), 3.98 (s, 2H, CH2, thiazolidinone), 4.08 (s, 5H,
ferrocene), 4.39 (s, 2H, ferrocene), 4.62 (s, 2H, ferrocene), 5.59 (s,
2H, ArCH2), 7.88–7.91 (m, 4H, Ar). Anal. Calcd for C24H20FeN4O3S:
C, 57.61; H, 4.03; N, 11.20. Found: C, 57.34; H, 4.20; N, 11.05.
4.2. Five-day growth inhibition assay
Compounds were tested for the ability to inhibit in vitro tachyzoite
(T. gondii RH-2 F (50839); ATCC, VA) and human foreskin fibroblast
(HFF; ATCC) growth for 120 h using a published colorimetric
assay8,19. Stock solutions of all compounds were 10mM in DMSO.
Serial 0.5 log10 dilutions (320–0.032 lM) of each compound were
tested. Data from three separate experiments were analysed and
the IC50, IC90, and TD50 calculated using Calcusyn software
(Biosoft, Cambridge, UK). The therapeutic index (TI), a measure of
specific anti-T. gondii activity, was calculated with the formula
shown under Table 1.
4.3. Invasion assay
The ferrocene-based derivatives (10lM) were examined for activity
directly on extracellular tachyzoites using an established immuno-
fluorescence-based red/green invasion assay19. This assay meas-
ures a compound’s ability to impede the parasite-driven host cell
entry of tachyzoites through the host cell plasma membrane.
Invaded (intracellular) tachyzoites are labelled green while tachy-
zoites attached to the surface, but unable to invade, are labelled
red. A decrease in the number of invaded tachyzoites relative to
vehicle [VHL (DMSO)] is indicative of invasion inhibition. A
decrease in the number of invaded plus attached tachyzoites rela-
tive to same of VHL is indicative of inhibition of attachment. Data
shown are mean values ± SEM of three independent experiments.
4.4. Replication assay
The ferrocene-based derivatives (10 lM) were also tested for
inhibitory activity against intracellular tachyzoites that had been
allowed to invade host cells and establish an infection for 2 h
before the addition of compound using an established immuno-
fluorescence-based protocol19. This assay measures a compound’s
ability to inhibit tachyzoite replication over a period of 24 h. The
numbers of parasitophorous vacuoles (PV) in experimentally
treated infected cells containing 1, 2, 4, or 8þ tachyzoites/vacuole
were enumerated, graphed, and compared to those of the VHL-
treated infected cells. Data for each size vacuole are shown as the
fraction of the total number of vacuoles counted in 10–15 fields.
Data shown were compiled from three independent experiments.
A decrease in the number of tachyzoites in a vacuole indicates
inhibition of replication. Toxoplasma gondii tachyzoites only repli-
cate within the PV inside the host cell with one cycle of replication
taking 6–8 h. Therefore, PVs containing 1, 2, 4, or 8 tachyzoites
indicates that 0, 1, 2, or 3 cycles of replication have been com-
pleted. Consequently, a decrease in the number of intravacuolar
tachyzoites relative to that of VHL indicates inhibition of replica-
tion21. Specifically, predominance, i.e. the largest fraction of the
total number, of PVs containing 1 or 2 tachyzoites indicates repli-
cation inhibition.
5. Results and discussion
We synthesised 33 new N-substituted thiazolidin-4-one derivatives
in high yield keeping constant three substituents at the N1-hydra-
zine portion of the scaffold (3-heptanone, 2-acetylthiophene and
acetylferrocene) from the good results obtained in our previous
works19. We explored the chemical space and the influence on the
biological activity of different groups (substituted aromatic and
bicyclic rings) at the lactam NH of the core nucleus. We have con-
firmed that this thiazolidin-4-one scaffold can be as effective, or
better than, the reference drug sulfadiazine in vitro against the
tachyzoites of T. gondii. In the five-day growth inhibition assay,
compounds were added only once, just before addition of tachy-
zoites, and thus were present for multiple cycles, up to 20, of
parasite replication. Specifically, compounds were tested against,
(i) the initial inoculum of tachyzoites as they attempt to invade
host cells, (ii) intracellular tachyzoites attempting to replicate
within the PV, and (iii) tachyzoites that have egressed from the ini-
tial infected cells and are moving out to infect neighbouring cells.
Thus, compounds that were highly efficacious in this assay inhib-
ited both host cell invasion and replication. Additionally, such
compounds were stable at 37 C and capable of being transported
not only across the cell plasma membrane, but across the PV
membrane. In this environment then, the best of the newly syn-
thesised thiazolidinones, in terms of IC50 and TI, were all those
deriving from acetylferrocene (3, 6, 12, 15, 18, 21, 24, 27, and
30), showing better values than reference compound sulfadiazine
(Table 1). The only exceptions were compounds 9 and 33. In par-
ticular, in the ferrocene-containing derivatives it is possible to
state that the substitution of the lactam NH influenced the bio-
logical activity with compound 30 as the best active and least
cytotoxic derivative. Moreover, regarding the influence of the sub-
stituent and its position on the aromatic ring from Table 1 it can
be extrapolated by analysing IC50 and TI data that 4-F (18)> 3-F
(15)> 2-F (12), 3-Cl (24) 2-Cl (21)> 4-Cl (27), and 2-NO2
(3)> 3-NO2 (6)> 4-NO2 (9). Only two derivatives (1, 13) in the
3-heptanone series displayed promising biological activity better
than reference drug. In general, phthalimide-based derivatives
(at the lactam NH) displayed minimal growth inhibitory activity.
We next evaluated the ability of the ferrocene-based derivatives
to act directly upon extracellular tachyzoites by using a standard
red/green invasion assay. This assay interrogates compounds for
inhibition of the first step in host cell infection, i.e. invasion and
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entry into susceptible cells. In this assay (Figure 1), cell-free purified
tachyzoites were incubated with a test compound (10lM), sulfadia-
zine (10 lM), or VHL for 20min at room temperature before being
added to HFF host cells. After allowing 1 h at 37 C for the tachy-
zoites to attach and invade, the cells were processed by immuno-
fluorescent staining. Extracellular/attached tachyzoites were
labelled red while intracellular/penetrated tachyzoites were labelled
green. We found that all of the ferrocene compounds, with the not-
able exceptions of compounds 3 and 27, significantly inhibited
invasion. Additionally, compounds 9, 15, and 30 significantly inhib-
ited attachment of tachyzoites to the HFF cells (Figure 1).
Lastly, the replication assay interrogates a compound’s ability to
inhibit an established intracellular Toxoplasma infection over the
relatively short period of 24 h (3–4 cycles of replication). In this
assay, robust inhibition of replication results in PVs containing only
one tachyzoite indicating that a treatment did not allow any repli-
cation to occur. Likewise, allowance of just one cycle of replication
results in a majority of PVs containing just two tachyzoites.
However, a predominance of PVs containing eight or more tachy-
zoites indicates absence of inhibitory activity over a 24 h period
(see detailed explanation above in Experimental Protocols). As
shown in Figure 2 the reference compound, sulfadiazine, showed
robust replication inhibition during this short period with a pre-
dominance of PVs containing just one or two tachyzoites.
Somewhat surprisingly, only one of the ferrocene derivatives, com-
pound 27, displayed fairly strong inhibition with the predominant
number of PVs containing two tachyzoites and 1% containing
eight or more. Treatment with derivatives 12 and 18 resulted in
modest inhibition with a predominance of PVs containing only two
tachyzoites but also 10–18% containing eight tachyzoites
(Figure 2). In light of the efficacy displayed in the five-day growth
inhibition and invasion assays, these results suggest that the major-
ity of the ferrocene derivatives exert their anti-Toxoplasma activity
primarily against the tachyzoite itself and are unable to affect intra-
cellular tachyzoites. This could be due to inefficient transport across
cell and PV membranes. This aspect will be investigated when
designing new chemical modifications within this scaffold.
6. Conclusions
We have synthesised a large number of N-substituted 1,3-thiazoli-
din-4-one derivatives to assess their inhibitory activity against
Toxoplasma tachyzoites. Approximately one-third of them stood
out as promising antiparasitic agents possessing an activity similar
or better than that of sulfadiazine against Toxoplasma and a com-
parable or lower cytotoxicity with respect to the reference drug.
Furthermore, we have also documented that among the most
active compounds, some derivatives strongly blocked the parasite
attachment and invasion of the host cell. From the comparison of
these data and the ones reported in our previous paper19, we can
assess that the presence of a ferrocene-based thiazolidinone is cru-
cial for the anti-Toxoplasma activity disregarding the type and
nature of the substituent at the lactam NH. However, a strong
improvement in this biological activity was observed by the intro-
duction of substituted benzyl groups with respect to phthalimide
or naphthalene ring at this position. These results demonstrated
the promising potential of this thiazolidinone scaffold for the
development of new anti-parasitic drugs.
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